TAIO PHAR | Sales 2022 | 268B 1.69B | Sales 2023 | 301B 1.9B | Capitalization | 452B 2.85B |
|---|---|---|---|---|---|
| Net income 2022 | 13.12B 82.88M | Net income 2023 | 19B 120M | EV / Sales 2022 | 0.71 x |
| Net cash position 2022 | 272B 1.72B | Net cash position 2023 | 256B 1.62B | EV / Sales 2023 | 0.65 x |
| P/E ratio 2022 |
35.2
x | P/E ratio 2023 |
23.8
x | Employees | 8,784 |
| Yield 2022 |
1.77% | Yield 2023 |
1.81% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.83% | 4 M€ | +6.90% | ||
| 0.79% | 14 M€ | +18.40% | ||
| 0.19% | 1,056 M€ | +4.47% |
Taisho Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products, and ethical drugs. The Company operates in two business segments. The Self-Medication segment is engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of ethical drugs. The other business is engaged in the leasing and management of real estate, as well as hotel management business.
Sector
-
Calendar
2024-07-31
- Q1 2024 Earnings Release (Projected)
